Cyclic enkephalin analogues with exceptional potency and selectivity for delta-opioid receptors. 1997

V J Hruby, and H Bartosz-Bechowski, and P Davis, and J Slaninova, and T Zalewska, and D Stropova, and F Porreca, and H I Yamamura
Department of Chemistry, University of Arizona, Tucson 85721, USA.

Superpotent and highly delta-opioid receptor selective cyclic peptides of the general formula H-Tyr-c[D-Pen-Gly-Phe(p-X)-Pen]-Phe-OH (where X = hydrogen or halogen) have been synthesized. In the binding assays the most selective and most potent compound is the p-bromophenyl-alanine-4 analogue (IC50 value = 0.19 nM, selectivity ratio = 21,000 for delta vs mu). In the GPI and MVD bioassays the most selective and most potent analogue is the p-fluoro-substituted analogue Tyr-[D-Pen-Gly-Phe(p-F)-Pen]-Phe-OH. In the MVD assay it has an exceptionally low IC50 value of 0.016 nM and a delta vs mu selectivity ratio of 45,000.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D010456 Peptides, Cyclic Peptides whose amino acid residues are linked together forming a circular chain. Some of them are ANTI-INFECTIVE AGENTS; some are biosynthesized non-ribosomally (PEPTIDE BIOSYNTHESIS, NON-RIBOSOMAL). Circular Peptide,Cyclic Peptide,Cyclic Peptides,Cyclopeptide,Orbitide,Circular Peptides,Cyclopeptides,Orbitides,Peptide, Circular,Peptide, Cyclic,Peptides, Circular
D011869 Radioligand Assay Quantitative determination of receptor (binding) proteins in body fluids or tissue using radioactively labeled binding reagents (e.g., antibodies, intracellular receptors, plasma binders). Protein-Binding Radioassay,Radioreceptor Assay,Assay, Radioligand,Assay, Radioreceptor,Assays, Radioligand,Assays, Radioreceptor,Protein Binding Radioassay,Protein-Binding Radioassays,Radioassay, Protein-Binding,Radioassays, Protein-Binding,Radioligand Assays,Radioreceptor Assays
D004745 Enkephalins One of the three major families of endogenous opioid peptides. The enkephalins are pentapeptides that are widespread in the central and peripheral nervous systems and in the adrenal medulla. Enkephalin
D006168 Guinea Pigs A common name used for the genus Cavia. The most common species is Cavia porcellus which is the domesticated guinea pig used for pets and biomedical research. Cavia,Cavia porcellus,Guinea Pig,Pig, Guinea,Pigs, Guinea
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D000700 Analgesics Compounds capable of relieving pain without the loss of CONSCIOUSNESS. Analgesic,Anodynes,Antinociceptive Agents,Analgesic Agents,Analgesic Drugs,Agents, Analgesic,Agents, Antinociceptive,Drugs, Analgesic
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013379 Substrate Specificity A characteristic feature of enzyme activity in relation to the kind of substrate on which the enzyme or catalytic molecule reacts. Specificities, Substrate,Specificity, Substrate,Substrate Specificities

Related Publications

V J Hruby, and H Bartosz-Bechowski, and P Davis, and J Slaninova, and T Zalewska, and D Stropova, and F Porreca, and H I Yamamura
May 1996, European journal of pharmacology,
V J Hruby, and H Bartosz-Bechowski, and P Davis, and J Slaninova, and T Zalewska, and D Stropova, and F Porreca, and H I Yamamura
January 1990, Journal of medicinal chemistry,
V J Hruby, and H Bartosz-Bechowski, and P Davis, and J Slaninova, and T Zalewska, and D Stropova, and F Porreca, and H I Yamamura
May 1983, Life sciences,
V J Hruby, and H Bartosz-Bechowski, and P Davis, and J Slaninova, and T Zalewska, and D Stropova, and F Porreca, and H I Yamamura
January 1994, Journal of medicinal chemistry,
V J Hruby, and H Bartosz-Bechowski, and P Davis, and J Slaninova, and T Zalewska, and D Stropova, and F Porreca, and H I Yamamura
June 1986, Life sciences,
V J Hruby, and H Bartosz-Bechowski, and P Davis, and J Slaninova, and T Zalewska, and D Stropova, and F Porreca, and H I Yamamura
August 2002, Journal of medicinal chemistry,
V J Hruby, and H Bartosz-Bechowski, and P Davis, and J Slaninova, and T Zalewska, and D Stropova, and F Porreca, and H I Yamamura
March 1988, Proceedings of the National Academy of Sciences of the United States of America,
V J Hruby, and H Bartosz-Bechowski, and P Davis, and J Slaninova, and T Zalewska, and D Stropova, and F Porreca, and H I Yamamura
November 2007, Journal of medicinal chemistry,
V J Hruby, and H Bartosz-Bechowski, and P Davis, and J Slaninova, and T Zalewska, and D Stropova, and F Porreca, and H I Yamamura
December 2019, Molecules (Basel, Switzerland),
V J Hruby, and H Bartosz-Bechowski, and P Davis, and J Slaninova, and T Zalewska, and D Stropova, and F Porreca, and H I Yamamura
September 1990, International journal of peptide and protein research,
Copied contents to your clipboard!